Skip to content

Contact +44 (0) 20 7060 7474 email us

Astellas

Astellas Pharma Inc.: PharmaVitae Profile

 

Publication Date February 2009
Publisher Datamonitor
Product Type Report
Pages 141
ISBN Number not applicable
Product Code DAT01661

Price

£1,990.00
approximately: $3,013 | €2,221

pdf

Buy Now

print £3,060 ($4,633 | €3,415)

Buy Now

Order above formats by FAX

Order by Fax

Summary

Introduction
This analysis examines the historical and forecast performance for Astellas in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope



Highlights



Reasons to Purchase


  • Benchmark Astellas's performance against key rivals in the prescription pharmaceutical sector
  • Determine the long-term outlook of Astellas's diverse prescription pharmaceutical portfolio
  • Evaluate the unique corporate strategies being pursued by Astellas in its domestic Japanese market and in the US

    • Contents

    • CHAPTER 1 ABOUT THIS PROFILE
      • Executive summary
      • Quarterly news update
      • Company introduction
      • Company sales
      • Company financials
      • Key products and competitors
      • Data sourcing
      • Sales data
      • Analyst consensus
    • CHAPTER 2 EXECUTIVE SUMMARY
      • Key findings
      • Prescription pharmaceutical sales performance, 2001-13
      • Financial performance, 2001-13
      • Astellas: PharmaVitae forecasts at a glance
      • Strategic insight
      • M&A helps reinforce focus on Rx pharmaceuticals
      • Cost containment and share buybacks drive investor returns post-merger
      • Flagship organ rejection franchise likely to exhibit strong defense against generic compeition
      • Lifecycle management and generic insulation vital in sustaining medium-term organ rejection revenues
      • Long-term focus on organ rejection underscored by continuing pipeline efforts
      • SWOT analysis
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
    • CHAPTER 3 QUARTERLY NEWS UPDATE
      • Product developments
      • Deals and alliances
      • Product deals
      • Technology deals
      • Company announcements
      • Future product milestones
    • CHAPTER 4 COMPANY INTRODUCTION
      • Key findings
      • Background
      • Key corporate developments
      • M&A history
      • Merger of Yamanouchi and Fujisawa
      • Acquisiiton of Agensys
      • Current corporate structure
      • Prescription (Rx) pharmaceuticals
      • Other
    • CHAPTER 5 COMPANY SALES
      • Key findings
      • Prescription pharmaceutical sales and growth rate analysis, 2001-13
      • Historical analysis
      • Forecast analysis
      • Product analysis
      • Product analysis, 2001-07
      • Growth drivers
      • Growth resistors
      • Product analysis, 2007-13
      • Growth drivers
      • Growth resistors
      • Therapy area analysis
      • Therapy area analysis, 2001-07
      • Therapy area analysis, 2007-13
      • Therapy area focus, 2001-13
      • Geographic analysis
      • Geographic analysis, 2001-07
      • Geographic analysis, 2007-13
      • Geographic focus, 2001-13
      • Launch/core/expiry analysis
      • Explanation of launch/core/expiry analysis
      • Launch analysis, 2007-13
      • Core analysis, 2007-13
      • Expiry analysis, 2007-13
      • Launch/core/expiry configuration, 2007-13
      • Molecule type analysis
      • Molecule type analysis, 2001-07
      • Molecule type analysis, 2007-13
      • Externalization analysis
      • Externalization analysis, 2001-07
      • Externalization analysis, 2007-13
    • CHAPTER 6 COMPANY FINANCIALS
      • Key findings
      • Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07
      • Financial statements, 2001-07
      • Profit and loss account, 2001-07
      • Balance sheet, 2001-07
      • Operating costs and profit analysis
      • Operating costs and profit analysis, 2001-07
      • Operating cost ratio and profit margin analysis, 2001-07
      • Operating cost ratio and profit margin analysis, 2007-13
      • Operating costs and profit analysis, 2007-13
      • Return on capital employed analysis
      • Capital employed analysis, 2001-07
      • Return on capital employed (RoCE) analysis, 2001-07
      • Market capitalization analysis
      • Market capitalization analysis, 2001-07
      • Total shareholder returns analysis, 2001-07
    • CHAPTER 7 KEY PRODUCTS AND COMPETITORS
      • Key findings
    • Overview
      • Cardiovascular
      • Micardis
    • Overview
      • Sales forecast
      • Lipitor
    • Overview
      • Sales forecast
      • Kynapid
    • Overview
      • Sales forecast
      • Immunology and inflammation
      • Prograf/Advagraf
    • Overview
      • Sales forecast
      • Urology and gender-specific health
      • Vesicare
    • Overview
      • Sales forecast
      • Harnal
    • Overview
      • Sales forecast
      • Infectious diseases
      • Arbelic
    • Overview
      • Sales forecast
    • CHAPTER 8 APPENDIX
      • R&D pipeline
      • References
      • Abbreviations
      • Exchange rates
    • List of Tables
      • Table 1: Astellas - PharmaVitae forecasts at a glance
      • Table 2: Post-merger financial performance of Astellas ($m), 2005-07
      • Table 3: Astellas key product developments, 2008
      • Table 4: Astellas product deals and alliances, 2008
      • Table 5: Astellas technology deals and alliances, Q1 2008
      • Table 6: Astellas company announcements, 2008
      • Table 7: Astellas future product milestones, 2009-10
      • Table 8: Astellas product portfolio overview ($m), 2001-07
      • Table 9: Astellas product portfolio overview ($m), 2007-13
      • Table 10: Astellas product portfolio overview ($m), 2001-07
      • Table 11: Astellas product portfolio overview ($m), 2007-13
      • Table 12: Astellas portfolio overview by geographic region ($m), 2001-07
      • Table 13: Astellas portfolio overview by geographic region ($m), 2007-13
      • Table 14: Astellas launch portfolio overview ($m), 2007-13
      • Table 15: Astellas core portfolio overview ($m), 2007-13
      • Table 16: Astellas expiry portfolio overview ($m), 2007-13
      • Table 17: Astellas portfolio overview by molecule type ($m), 2001-07
      • Table 18: Astellas product portfolio overview by molecule type ($m), 2007-13
      • Table 19: Astellas portfolio overview by source ($m), 2001-07
      • Table 20: Astellas portfolio overview by source ($m), 2007-13
      • Table 21: Total Astellas sales by business unit ($m), 2001-07
      • Table 22: Astellas profit and loss account ($m), 2001-07
      • Table 23: Astellas balance sheet ($m), 2001-07
      • Table 24: Astellas operating revenue/cost analysis ($m), 2001-07
      • Table 25: Astellas operating cost ratio analysis (% of total revenues), 2001-07
      • Table 26: Astellas operating cost ratio analysis (% of total revenues), 2007-13
      • Table 27: Astellas operating revenue/cost analysis ($m), 2007-13
      • Table 28: Astellas capital employed ($m), 2001-07
      • Table 29: Astellas EBIT return on capital employed ($m), 2001-07
      • Table 30: Astellas EBIT pre-tax return/capital employed driver analysis (%), 2001-07
      • Table 31: Astellas market capitalization ($ billion), 2001-07
      • Table 32: Astellas total shareholder returns (annual %), 2001-07
      • Table 33: Key products overview
      • Table 34: Micardis: overview
      • Table 35: Micardis HCT: overview
      • Table 36: Micardis: sales forecast ($m), 2007-13
      • Table 37: Micardis HCT: sales forecast ($m), 2007-13
      • Table 38: Lipitor: overview
      • Table 39: Lipitor: sales forecast ($m), 2007-13
      • Table 40: Kynapid: overview
      • Table 41: Kynapid: sales forecast ($m), 2007-13
      • Table 42: Prograf: overview
      • Table 43: Advagraf: overview
      • Table 44: Prograf: sales forecast ($m), 2007-13
      • Table 45: Advagraf: sales forecast ($m), 2007-13
      • Table 46: Vesicare: overview
      • Table 47: Vesicare: sales forecast ($m), 2007-13
      • Table 48: Harnal: overview
      • Table 49: Harnal: sales forecast ($m), 2007-13
      • Table 50: Arbelic: overview
      • Table 51: Arbelic: sales forecast ($m), 2007-13
      • Table 52: Astellas's R&D pipeline (Phase I-registration)
      • Table 53: Exchange rates, 2007
    • List of Figures
      • Figure 1: Astellas prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
      • Figure 2: Astellas's financial performance ($m), 2001-13
      • Figure 3: Creation of a leading Japanese pharmaceutical player
      • Figure 4: Astellas set to overtake Takeda in Japan, sales ($m), 2007-13
      • Figure 5: Tacrolimus franchise sales ($m), 2007-13
      • Figure 6: Astellas SWOT analysis
      • Figure 7: Current corporate structure
      • Figure 8: Astellas prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
      • Figure 9: Astellas key sales growth driver and resistors ($m), 2001-07
      • Figure 10: Astellas key sales growth drivers and resistors ($m), 2007-13
      • Figure 11: Astellas prescription pharmaceutical sales by therapy area ($m), 2001-13
      • Figure 12: Astellas prescription pharma sales by therapy area (% of total), 2001-13
      • Figure 13: Astellas prescription pharmaceutical sales by geographic region ($m), 2001-13
      • Figure 14: Astellas growth drivers and resistors by geographic region ($m), 2001-07
      • Figure 15: Astellas drivers and resistors by geographic region ($m), 2007-13
      • Figure 16: Astellas prescription pharmaceutical sales by geographic region (% of total), 2001-13
      • Figure 17: Astellas launch/core/expiry configuration ($m), 2007-13
      • Figure 18: Astellas prescription pharmaceutical sales by molecule type ($m), 2001-13
      • Figure 19: Astellas prescription pharmaceutical sales by source ($m), 2001-13
      • Figure 20: Astellas growth drivers and resistors by source ($m), 2001-07
      • Figure 21: Astellas growth drivers and resistors by source ($m), 2007-13
      • Figure 22: Astellas operating revenue/cost analysis ($m), 2001-13
      • Figure 23: Astellas operating cost ratio analysis (% of total revenues), 2001-13
      • Figure 24: Astellas return on capital employed, EBIT margin and capital turnover, 2001-07
      • Figure 25: Return on capital employed formula
      • Figure 26: Astellas market capitalization ($ billion), 2001-07
      • Figure 27: Astellas total shareholder returns vs. S&P 500 ($m), 2001-07